1.
Clin Infect Dis
; 51(9): 1070-2, 2010 Nov 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20887204
RESUMO
We previously demonstrated that 4‐site, intradermal, single‐visit rabies booster vaccination provides immunogenicity greater than that provided by the standard 2‐booster, 2‐visit regimen. The regimen has been routinely used in 5116 patients since 1998 without any treatment failure. It is not only effective but also saves vaccine costs and transportation expenses and improves compliance.